What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature

Journal of the European Academy of Dermatology and Venereology

Volumn 24, Issue SUPPL. 2, 2010, Pages 10-16

  Puzenat, E ^a   Bronsard, V ^b   Prey, S ^c   Gourraud, P A ^d,e   Aractingi, S ^f   Bagot, M ^g   Cribier, B ^h   Joly, P ⁱ   Jullien, D ^j   Le Maitre, M ^k   Paul, C ^c   Richard Lallemand, M A ^l   Ortonne, J P ^b   Aubin, F ^a  

^a UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^b UNIVERSITÉ CÔTE D'AZUR   (France)

^c UNIVERSITÉ DE TOULOUSE   (France)

^d TOULOUSE UNIVERSITY HOSPITAL   (France)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f HÔPITAL TENON   (France)

^g SAINT LOUIS HOSPITAL   (France)

^h Dermatology Department   (France)

ⁱ ROUEN UNIVERSITY HOSPITAL   (France)

^j EDOUARD HERRIOT HOSPITAL   (France)

^k Dermatologist   (France)

^l AIX MARSEILLE UNIVERSITY   (France)

more..

Author keywords

PASI; Psoriasis; Score; Severity; Systematic review

Indexed keywords

BEER SHEVA PSORIASIS SEVERITY SCORE; BODY SURFACE AREA SCORE; CONSTRUCT VALIDITY; CONTENT VALIDITY; COPENHAGEN PSORIASIS SEVERITY INDEX; DERMATOLOGY INDEX OF DISEASE SEVERITY; DISEASE SEVERITY; GOLD STANDARD; HUMAN; INTERNAL CONSISTENCY; INTERRATER RELIABILITY; INTRARATER RELIABILITY; LATTICE SYSTEM PHYSICIAN GLOBAL ASSESSMENT; MEDICAL LITERATURE; NATIONAL PSORIASIS FOUNDATION PSORIASIS SCORE SYSTEM; OUTCOME ASSESSMENT; PHYSICIAN GLOBAL ASSESSMENT; PRIORITY JOURNAL; PSORIASIS AREA SEVERITY INDEX; PSORIASIS LONG BASED AREA SEVERITY INDEX; PSORIASIS VULGARIS; RESPONSE TO TREATMENT SCORE; REVIEW; SALFORD PSORIASIS INDEX; SCORING SYSTEM; SELF ADMINISTERED PSORIASIS AREA SEVERITY INDEX; SYSTEMATIC REVIEW; HEALTH CARE QUALITY; OBSERVER VARIATION; PROCEDURES; PSORIASIS; SEVERITY OF ILLNESS INDEX;

HUMANS; OBSERVER VARIATION; PSORIASIS; QUALITY ASSURANCE, HEALTH CARE; SEVERITY OF ILLNESS INDEX;

EID: 77749326623     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2009.03562.x     Document Type: Review

References (41)

1. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007 370 : 263 271.
2. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004 9 : 136 139.
3. Schmitt JM, Ford DE. Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis. Dermatology 2006 213 : 102 110.
4. Naldi L, Svensson A, Diepgen T et al. Randomized clinical trials for psoriasis 1977-2000: the EDEN survey. J Invest Dermatol 2003 120 : 738 741.
5. Committee for medicinal products for human use. Guidelines on clinical investigation of medicinal products for the treatment of psoriatic arthritis. European Medicines Agency, Emea, 2005 1 10.
6. Ashcroft DM, Wan Po AL, Williams HC, Griffiths CE. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol 1999 141 : 185 191.
7. Berth-Jones J, Grotzinger K, Rainville C et al. A study examining inter- and intrarater reliability of three scales for measuring severity of psoriasis: Psoriasis Area and Severity Index, Physician's Global Assessment and Lattice System Physician's Global Assessment. Br J Dermatol 2006 155 : 707 713.
8. Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bulletin 1979 86 : 420 427.
9. Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika 1951 16 : 297 334.
10. Schmitt J, Langan S, Williams HC, on behalf of the European Dermato-Epidemiology Network. What are the best outcome measurements for atopic eczema? A systematic review J Allergy Clin Immunol 2007 120 : 1389 1398.
11. Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol 2004 51 : 563 569.
12. Kirby B, Fortune DG, Bhushan M et al. The Salford Psoriasis Index : an holistic measure of psoriasis severity. Br J Dermatol 2000 142 : 728 732.
13. Kirby B, MRCPI, Richard HI et al. Physical and psychologic measures are necessary to assess overall psoriasis severity. J Am Acad Dermatol 2001 45 : 72 76.
14. Feldman S, Clark AR, Venkat AP et al. The Self-Administered Psoriasis Area and Severity Index provides an objective measure of psoriasis severity. Br J Dermatol 2005 152 : 368 403.
15. Fleischer AB, Feldmann R, Dekle CL. The SAPASI is valid and responsive to psoriasis disease severity change in a multicenter clinical trial. J Dermatol 1999 26 : 210 215.
16. Feldman SR, Fleischer AB, Reboussin DM et al. The Self-Administered Psoriasis Area and Severity Index Is Valid and Reliable. J Invest Dermatol 1996 106 : 183 186.
17. Sampogna F, Sera F, Mazzotti E et al. Performance of the self-administered psoriasis area and severity index in evaluating clinical and sociodemographic subgroups of patients with psoriasis. Arch Dermatol 2003 139 : 353 358.
18. Fleischer AB, Rapp SR, Reboussin DM, Vanathos JC, Feldman SR. Patient measurement of psoriasis disease severity with a structured instrument. J Invest Dermatol 1994 102 : 967 969.
19. Ramsay B, Lawrence CM. Measurement of involved surface area in patients with psoriasis. Br J Dermatol 1991 124 : 565 570.
20. Tiling-Grosse S, Rees J. Assessment of area of involvement in skin disease: a study using schematic figure outlines. Br J Dermatol 1993 128 : 69 74.
21. Revicki D, Hays RD, Cella D, Sloan J. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol 2010 63 : 28 36.
22. Turner D, Schünemann HJ, Griffith LE et al. The minimal detectable change cannot reliably replace the minimal important difference. J Clin Epidemiol 2010 63 : 28 36.
23. Stern RS, Armstrong RB, Anderson TF et al. Effect of continued ultraviolet B phototherapy on the duration of remission of psoriasis: a randomized study. J Am Acad Dermatol 1986 15 : 546 552.
24. Long CC, Finlay AY, Averill RW. The rule of hand: 4 hand areas = 2 FTU = 1 g. Arch Dermatol 1992 128 : 1129 1130.
25. Schmitt J, Wozel G. The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology 2005 210 : 194 199.
26. Gottlieb AB, Chaudhari U, Baker DG, Perate M, Dooley LT. The National Psoriasis Foundation Psoriasis Score (NPF-PS) system versus the Psoriasis Area Severity Index (PASI) and Physician's Global Assessment (PGA): a comparison. J Drugs Dermatol 2003 2 : 260 266.
27. Weiss SC, Kimball AB, Liewehr DJ, Blauvelt A, Turner ML, Emanuel EJ. Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol 2002 4 : 512 518.
28. Jenner N, Campbell J, Plunkett A, Marks R. Cost of psoriasis: a study on the morbidity and financial effects of having psoriasis in Australia. Australas J Dermatol 2002 43 : 255 261.
29. Jacobson CC, Kimball AB. Rethinking the Psoriasis Area and Severity Index: the impact of area should be increased. Br J Dermatol 2004 151 : 381 387.
30. Berth-Jones J, Thompson J, Papp K, Copenhagen Psoriasis Working Group. A study examining inter-rater and intrarater reliability of a novel instrument for assessment of psoriasis: the Copenhagen Psoriasis Severity Index. Br J Dermatol 2008 159 : 407 412.
31. van de Kerkhof PC, Kragballe K, Austad J et al. Psoriasis: severity assessment in clinical practice. Conclusions from workshop discussions and a prospective multicentre survey of psoriasis severity. Eur J Dermatol 2006 16 : 167 171.
32. Zschocke I, Hammelmann U, Augustin M. Therapeutic benefits in dermatological therapy. Evaluation of therapy from the physician's and patient's perspective in psoriasis and atopic dermatitis. Hautarzt 2005 56 : 839 842, 844-846.
33. Revicki DA, Willian MK, Menter A, Saurat JH, Harnam N, Kaul M. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis. Dermatology 2008 216 : 260 270.
34. Schäfer I, Hacker J, Rustenbach SJ, Radtke M, Franzke N, Augustin M Concordance of the Psoriasis Area and Severity Index (PASI) and patient-reported outcomes in psoriasis treatment. Eur J Dermatol. 2009 Oct 12 [Epub ahead of print].
35. Cohen AD, Van Dijk D, Naggan L, Vardy DA. Effectiveness of climatotherapy at the Dead Sea for psoriasis vulgaris: a community-oriented study introducing the "Beer Sheva Psoriasis Severity Score". J Dermatolog Treat 2005 16 : 308 313.
36. Cohen AD, Van Dijk D, Naggan L, Vardy DA. Factor analysis of the Beer Sheva Psoriasis Severity Score (BPSS). Isr Med Assoc J 2008 10 : 419 423.
37. Hahn HB, Chuang TY. Using the Dermatology Index of Disease Severity (DIDS) to assess the responsiveness of dermatitis. Clin Exp Dermatol 2006 31 : 19 22.
38. Faust HB, Gonin R, Chuang TY, Lewis CW, Melfi CA, Farmer ER. Reliability testing of the dermatology index of disease severity (DIDS). An index for staging the severity of cutaneous inflammatory disease. Arch Dermatol 1997 133 : 1443 1448.
39. Vardy DA, Guberman D, Lichtenstein DA, Klaus SN. Assessment of severity score in patients with psoriasis. Br J Dermatol 1993 129 : 349 350.
40. Henseler T, Schmitt-Rau K. A comparison between BSA, PASI, PLASI and SAPASI as measures of disease severity and improvement by therapy in patients with psoriasis. Int J Dermatol 2008 47 : 1019 1023.
41. Weisman S, Pollack CR, Gottschalk RW. Psoriasis disease severity measures: comparing efficacy of treatments for severe psoriasis. J Dermatolog Treat 2003 14 : 158 165.